# Sean X. Hu

> Sean X. Hu is the President and CEO of Rapafusyn Pharmaceuticals, a Baltimore-based biotech spun out of Johns Hopkins that is building a library of natural-product-like macrocycles it calls RapaGlues. He is a genomics PhD turned Wharton MBA turned management consultant turned operator, with prior stops at Bristol Myers Squibb, CuraGen, Illumina, AT Kearney, IMS, Bionest, BioStrat, GlobalData, and Avotres. In September 2025 he closed an oversubscribed $44M Series A led by BioTrack Capital and Yonjin Capital to push RapaGlues into difficult-to-drug targets.

- **Role:** President and CEO at Rapafusyn Pharmaceuticals
- **Organizations:** Rapafusyn Pharmaceuticals, Avotres Inc., GlobalData PLC, BioStrat Advisory LLC, Bionest USA, IMS Consulting, AT Kearney, Illumina, CuraGen, Bristol Myers Squibb, BioKatalyst
- **Education:** BS, Organic Chemistry, Peking University, PhD, Genomics, New York University, MBA, Entrepreneurship & Strategic Management, Wharton School, University of Pennsylvania
- **Known for:** Closed oversubscribed $44M Series A for Rapafusyn in September 2025, Rapafusyn selected to join the Roche Accelerator, Built and ran Avotres Inc., a clinical-stage biopharma targeting regulatory T cells

## Career timeline

- **1990s** — PhD in Genomics at NYU
- **late 1990s** — Operating roles at Bristol Myers Squibb, CuraGen, Illumina
- **2001** — MBA from Wharton
- **2000s-2010s** — Consulting at AT Kearney, IMS Consulting
- **2010s** — Managing Partner roles at Bionest USA and BioStrat Advisory LLC
- **2010s-2020s** — SVP, Head of Healthcare Consulting Americas at GlobalData PLC
- **2019** — Founding President of BioKatalyst
- **2020s** — CEO of Avotres Inc.
- **2024** — Appointed CEO of Rapafusyn Pharmaceuticals
- **2025-09** — Closed oversubscribed $44M Series A

## Achievements

- Closed oversubscribed $44M Series A for Rapafusyn in September 2025
- Rapafusyn selected to join the Roche Accelerator
- Built and ran Avotres Inc., a clinical-stage biopharma targeting regulatory T cells
- Head of Healthcare Consulting Americas at GlobalData PLC
- Founding President of BioKatalyst
- Adjunct Professor at Chinese National Human Genome Center (Shanghai) and Senior Advisor / Visiting Professor at Beijing Genomics Institute
- Editorial Board Member, Personalized Medicine (peer-reviewed journal)

## Latest updates

- **2025-09** — Rapafusyn closed an oversubscribed $44M Series A led by BioTrack Capital and Yonjin Capital.
- **2025-01** — Rapafusyn showcased its molecular glue drug discovery platform at the Wuxi Global Forum.

## Links

- Website: https://rapafusyn.com
- LinkedIn: https://www.linkedin.com/in/sean-x-hu-a597332/

---

Profile page: https://yespress.io/sean-hu
Published by YesPress — https://yespress.io
Last updated: 2026-07-08